Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemiparin therapeutic vs prophylactic dose in hospitalized COVID-19 patients
2020-001548-24Phase 2Terminated
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of bemiparin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fundación de Investigación HM Hospitales. Primary endpoint: Combined worsening variable at day 10. Started Jul 2020; status: terminated.
02
Drugs
bemiparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001548-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001548-24.